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Abstract
Background: Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in young children
worldwide, and no vaccine is currently available. Inactivated RSV vaccines tested in the 1960’s led to vaccine-enhanced
disease upon viral challenge, which has undermined RSV vaccine development. RSV infection is increasingly being
recognized as an important pathogen in the elderly, as well as other individuals with compromised pulmonary immunity. A
safe and effective inactivated RSV vaccine would be of tremendous therapeutic benefit to many of these populations.
Principal Findings: In these preclinical studies, a mouse model was utilized to assess the efficacy of a novel, nanoemulsion-
adjuvanted, inactivated mucosal RSV vaccine. Our results demonstrate that NE-RSV immunization induced durable, RSV-
specific humoral responses, both systemically and in the lungs. Vaccinated mice exhibited increased protection against
subsequent live viral challenge, which was associated with an enhanced Th1/Th17 response. In these studies, NE-RSV
vaccinated mice displayed no evidence of Th2 mediated immunopotentiation, as has been previously described for other
inactivated RSV vaccines.
Conclusions: These studies indicate that nanoemulsion-based inactivated RSV vaccination can augment viral-specific
immunity, decrease mucus production and increase viral clearance, without evidence of Th2 immune mediated pathology.
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Introduction
Respiratory syncytial virus (RSV) infection is a major cause of
respiratory illness, particularly in infants. It is estimated by the
CDC that every year RSV is associated with approximately
125,000 pediatric hospitalizations in the United States, at an
annual cost of over $300,000,000 [1]. Despite the generation of
RSV-specific adaptive immune responses, RSV infection does not
confer protective immunity in humans and recurrent infections are
common [2,3]. While RSV is especially detrimental in very young
infants whose airways are small and easily occluded, RSV is also
becoming recognized as an important pathogen in transplant
recipients, the elderly, and patients with chronic lung diseases,
especially chronic obstructive pulmonary disease (COPD) and
asthma. Recent data suggest that combined U.S. mortality from
RSV in all ages is approximately 30/100,000 from 1990–2000,
with an average annual mortality of over 17,000 [4,5]; however
these numbers likely underestimated adult disease, as RSV
infection in this populations has not been consistently followed.
In infants, severe RSV infection has been linked with the
subsequent development of asthma in later childhood. Addition-
ally, RSV is recognized as an important pathogen in the elderly
and/or immunocompromised patients, and exacerbation of
chronic lung disease. Thus, RSV causes severe lung disease in
the young and the elderly. It is particularly a problem in immuno-
compromised individuals, and is associated with significant
mortality in these populations.
Given the above information, an ideal RSV vaccine would be
immunogenic and safe in all the populations susceptible to disease
from the infection. In general, however, inactivated RSV vaccines
have exhibited poor immunogenicity. Conversely, live-attenuated
vaccines, which often cause infection-related symptoms, have had
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The absence of an effective vaccine is reflected in the mortality
rate due to severe RSV. An estimated ninety nine percent of
deaths due to RSV occur in the developing world, where
supportive therapy is not available [6]. Live attenuated viral
vaccines will not solve this problem, as they typically require cold
storage prior to use, a significant obstacle to their use in remote
areas. Thus, an ambient temperature-stable RSV vaccine would
be of significant public health benefit worldwide.
Another unique problem associated with RSV vaccination
occurred in the late 1960s, following vaccination of children with
an alum-precipitated formalin-inactivated RSV (FI-RSV) vaccine
preparation. This vaccine failed, causing severe exacerbated
disease upon live RSV infection. Considerable research effort
over the past several decades has sought to determine the
mechanisms responsible for this phenomenon, referred to as
‘‘vaccine-enhanced disease’’ or ‘‘immunopotentiation’’. Evidence
also clearly demonstrates that the use of alum promotes Th2
responses [7,8,9,10] and therefore the choice of adjuvant must be
made carefully.
Nanoemulsion-based mucosal vaccination has been demon-
strated to be efficacious in animal models at preventing infection
with a number of pathogens, including Anthrax, Influenza,
Vaccinia (as a model for smallpox vaccination), HIV, and
Hepatitis B [11,12,13,14,15]. In these studies, we tested the
immunogenicity and efficacy of an intranasal nanoemulsion-
adjuvanted inactivated RSV vaccine (NE-RSV) in a mouse model
of RSV. NE-RSV induced RSV specific IgG and IgA responses,
and enhanced viral clearance upon challenge. In contrast to alum,
however, it did not result in Th2 mediated immunopotentiation.
Our results demonstrate that this novel mucosal vaccine provides a
unique approach for effective RSV vaccination.
Results
Nanoemulsion effectively inactivates RSV
Previous studies have demonstrated that novel water-in-oil
nanoemulsions exhibit broad microbicidal activity [16,17,18,
19,20]. The water-miscible emulsion droplets (,400 nm size)
are believed to inactivate viruses by the physical disruption of the
viral envelope. To determine whether the nanoemulsion formu-
lation exhibits virucidal activity against RSV, 10
6 PFU of RSV
(Line 19) was incubated with varying concentrations of NE, and
then used to infect Type I IFN deficient Vero cells. After the virus
was incubated with 2% nanoemulsion for one hour or 1%
nanoemulsion for 3 hrs, there was no viable virus as assessed by
standard plaque assay (Fig. 1). Inactivation of the virus by NE was
further confirmed by serial passage of NE treated RSV in Hep2
cells, followed by plaque assay. After two amplifying passages in
Hep2 cells, no plaques were detected from 3 hr incubated NE-
RSV, as compared to .10
6 PFU/ml when the virus was treated
with media as a control. These results indicate that NE effectively
inactivates RSV at greater than 10 fold lower concentrations than
the NE concentrations in the vaccine formulation.
NE-RSV immunization induces durable RSV-specific
antibodies
We next determined whether NE-RSV vaccination would
promote the type of antibody response associated with protection
against subsequent RSV infection. To examine this, mice were
immunized with two intranasal doses of NE-RSV (5 ul per nare
containing ,10
5 virus particles), separated by 28 days. Mice
were assessed for the presence of RSV-specific serum antibodies
immediately prior to the first vaccination, and then every two
weeks thereafter. Significant RSV-specific serum responses were
observed following the second vaccination with NE-RSV
(Fig. 2A)., corresponding to an endpoint titer of 2
14 (Fig. 2B).
No significant decrease in RSV-specific antibodies was observed
up to six weeks after the second vaccination (Fig. 2A). The
antibody isotypes promoted by the vaccine included IgA, IgG2a,
IgG1, but notably, no increase in IgE was observed (Fig. 2C).
IgG1 and IgG2a responses were directed at both RSV F and
RSV G surface glycoproteins, as assessed via ELISA using
recombinant glycoproteins (Fig. 2D). Again, no virus specific IgE
antibodies were detected (data not shown). We next determined
whether vaccination could promote the induction of RSV-
specific antibodies locally in the lungs. Mice were vaccinated
twice with NE-RSV, and the bronchoalveloar lavage fluid (BAL)
Figure 1. Nanoemulsion effectively inactivates RSV. Nanoemulsion RSV (10
6 plaque forming units (PFU)) was incubated with nanoemulsion at
varying concentrations (0%–20%) and varying times (1 hr–3 hrs). The number of infectious virus particles was determined via plaque assay using Vero
cells. Control and nanoemulsion-incubated virus was used to infect sub-confluent Vero cells. RSV plaques at were visualized day 5 post-infection
using immunohistochemical techniques.
doi:10.1371/journal.pone.0021823.g001
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result in significant increases in IgA in the bronchoalveolar
lavage (Fig. 2E). Remarkably, a significant increase in RSV-
specific IgA in the lungs was detected as early as week 2 post-
vaccination.
To identify whether the antibodies generated in our study
displayed cross-reactivity, we utilized sera from vaccinated and
primary infected animals with direct ELISAs to other A strain
viruses. These viruses included A2, Line19, and a new clinical
isolate from Drs. Stokes Peebles and Marty Moore’s laboratories,
2–20 (unpublished virus stock). All of these viruses demonstrated a
significant reactivity with the vaccinated serum (Table 1). Thus,
our serum antibody reactivity appears to have the capacity to
provide cross-protective antibodies. Future studies will thoroughly
Figure 2. Intranasal vaccination of mice with NE-RSV results in RSV-specific antibody responses. Mice were immunized with NE-RSV
containing 10
5 virus particles at Day 0 and Day 28. In (A), the levels of RSV specific antibodies (IgG+IgM) in serum were determined at weeks 2, 4, 6, 8,
and 10 via ELISA using purified RSV protein. In (B), serum samples were serially diluted to obtain endpoints titers. In (C), RSV-specific IgA, IgG2a, IgG1,
and IgE were assessed at week 8 via isotype-specific ELISA. In (D), IgG2a and IgG1 antibodies specific for RSV F and G were assessed at week 8 via
isotype-specific ELISA using purified RSV F and G glycoproteins. In (E), RSV-specific IgA responses in bronchoalveolar lavage samples (BAL) were
assessed using an isotype-specific ELISA. Each time point represents the mean of a minimum of 5 samples +/2 SEM, and the experiment was
repeated with similar results. *=P,0.01.
doi:10.1371/journal.pone.0021823.g002
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and increase viral clearance.
NE-RSV immunization reduces viral load and
immunopathology following upper respiratory challenge
To examine whether vaccination with NE-RSV would affect
viral clearance and immunopathology, mice were immunized as
above, with two intranasal doses of NE-RSV (at day 0 and day
28), then challenged with live, infectious RSV intranasally (10
5
PFU) on day 56 post immunization. Intranasal inoculation of
mice with Line 19 RSV, leads to an infection that is associated
with a moderate form of disease phenotype, including mucus
hypersecretion and inflammation. The severity of this phenotype
in control and immunized animals was assessed using histologic
analysis and QPCR for viral and cytokine gene expression.
Compared to control mice, NE-RSV vaccinated mice exhibited
enhanced clearance of the virus, as assessed by the levels of RSV
transcripts in the lungs at day 4 post challenge (Fig. 3A). At day 8,
post-challenge, vaccinated mice exhibited attenuated mucus
hypersecretion, as assessed via histologic analysis (Fig. 3B), as
well the increased expression of the mucus-associated genes
Muc5ac and Gob5 (Fig. 3C). Additionally, no evidence of
eosinophilia was observed in mice vaccinated with NE-RSV
(5.4%63.3%) versus controls (6.3%62.5%) (Fig. 3B). The
increased viral clearance was associated with enhanced lung
expression of the Th1/Th17 associated cytokines IL-6, IL-12
p40, IFNc, and IL-17 (Fig. 4A). NE-RSV vaccinated mice also
showed enhanced production of chemokines CXCL10 and
CXCL9 in the BAL fluid after RSV challenge (Fig. 4B). This
was significant because CXCL10 has been previously shown by
our laboratory to play a critical role in host defense against RSV
via promoting CD8+ T cell responses [21]. These data indicate
that NE-RSV vaccination can attenuate RSV-induced upper
respiratory disease.
We next examined the cellular responses induced by viral
challenge in mice following NE-RSV vaccination (Fig. 5). As
compared to control RSV-infected mice, NE-RSV vaccinated
mice had increased CD4+ T cell responses in the lungs and BAL,
and increased RSV M82–90 specific CD8+ T cells in the lungs and
BAL (Fig. 5). Overall, these data demonstrate that vaccination
with NE-RSV promotes T cell-mediated immunity to RSV,
including an enhanced CD8+ cytolytic T cell response. This
indicates that the cellular immune response to RSV challenge was
enhanced for Th1/Tc1 in animals receiving NE-RSV vaccination.
NE-RSV immunization enhances immunity to lower
respiratory RSV challenge
Further studies were conducted to determine whether vacci-
nation with NE-RSV would improve viral clearance after a lower
respiratory challenge with RSV, which results in a more severe
clinical phenotype. Experiments were conducted with an
identical immunization and challenge protocol as that employed
for intranasal challenge, except that the mice were challenged
with RSV intratracheally, rather than intranasally, at Day 56. At
day 4 post-challenge, viral load was assessed in the lungs via
QPCR and via plaque assay. As assessed via QPCR, a significant
decrease in the transcript levels for RSV G and RSV F were
detected in the lungs of NE-RSV vaccinated mice (Fig. 6A). A
reduction in RSV N was also observed, though this did not reach
statistical significance. More compelling, compared to control
RSV infected mice, an 88% reduction in plaque forming units
(PFU) was found in the lungs of NE-RSV vaccinated mice
(Fig. 6B). These data indicate that NE-RSV vaccine dramatically
improves viral clearance in the following lower respiratory
challenge.
NE-RSV does not promote airway hyperreactivity, airway
eosinophilia, nor the induction of Th2 cytokines
As previously reported, vaccination with FI-RSV promotes
the development of airway hyperreactivity (AHR) and
eosinophilia upon live viral challenge [22,23,24]. Although
the cytokine profile and RSV antibody isotype distribution
seen in NE-RSV vaccinated mice did not suggest that
pathophysiology would be increased by vaccination, we
wanted to confirm that vaccination did not promote airway
hyper-reactivity, or other evidence of immunopotentiation.
Compared to control RSV infected mice, NE-RSV immunized
mice exhibited only baseline increases in airway resistance
following intravenous methacholine challenge (Fig. 7A). Sim-
ilarly, no significant eosinophilia was observed in NE-RSV
vaccinated mice (Table 2). In contrast, we observed a
significant increase in BAL neutrophils after RSV challenge
in NE-RSV vaccinated mice with the increased IL-17A,
(Table 2). To further examine whether there was any evidence
of Th2-mediated immunopotentiation, cytokine profiles were
assessed in bronchoalveolar lavage and lung homogenates via
multiplex antibody-based assay (Bioplex). NE-RSV vaccination
did not result in significantly enhanced Th2 cytokine responses
(Fig. 7B), but showed an enhanced IFNc and IL-17 response
(Fig. 7B).
Since much of the concern regarding RSV vaccines has
centered on immunopathology generated by the original formalin
inactivated vaccine (FI-RSV), we sought to compare the immune
responses generated by NE-RSV versus FI-RSV. In these studies
immune responses generated by the two vaccines were directly
compared. Mice were vaccinated twice intranasally with NE-
RSV, separated by four weeks, as previously described. FI-RSV
was administered intramuscularly (IM), six weeks prior to live
viral challenge, and mice were assessed at day 8 post-infection.
Compared to unvaccinated mice, only FI-RSV vaccinated mice
had significantly enhanced mucus hypersecretion (Fig. 8A). Also,
neither unvaccinated mice nor NE-RSV vaccinated mice had
evidence of airway eosinophilia (Fig. 8B), which is a hallmark of
vaccine enhanced disease [25]. In stark contrast to these findings,
FI-RSV vaccinated mice had significant airway eosinophilia, with
approximately 500,000 total eosinophils in their BAL (Fig. 8B).
Consistent with our previous data, NE-RSV vaccination resulted
in a more modest increase in neutrophils to the airways (Fig. 8B).
Table 1. Cross-reactivity of IgG1 antibodies induced by NE-
RSV vaccination.
Line 19 Emory 2–20 A2
Naı ¨ve 0.04760.002 0.04660.001 0.05060.001
NE-RSV Vaccinated 1.99560.112** 2.17260.114** 2.09560.098**
Primary RSV 0.56760.243* 0.60160.284* 0.60960.245*
Mice were vaccinated with NE-RSV twice and challenged with live RSV Line 19.
Serum from vaccinated (NE-RSV vaccinated) and unvaccinated (Primary RSV)
were obtained at day 8 post-challenge. Antibody binding to the various RSV
strains was determined via isotype-specific ELISA. Values represent the mean
OD 6 SEM (N=3–4 animals per group)
*=p, 0.05 versus naive,
**=p, 0.05 versus primary RSV, as determined by ANOVA followed by Dunnett’s
post test.
doi:10.1371/journal.pone.0021823.t001
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associated with increased expression of IL-13 in the lungs; which
was not present in NE-RSV vaccinated mice (Fig. 9A). Consistent
with the increase in BAL neutrophils in NE-RSV vaccinated
mice, NE-RSV vaccination promoted IL-17 immunity (Fig. 9A).
In addition, while vaccination with either NE-RSV or FI-RSV
augmented the total RSV-specific antibody response (IgG, IgM,
IgG1, and IgA) only FI-RSV vaccinated mice had a significant
increase RSV-specific IgE. In contrast, NE-RSV vaccinated mice
had increased RSV-specific IgG2a, an isotype associated with
Th1 immune responses. Cumulatively, these data demonstrate
that NE-RSV promotes clearance of RSV via mechanisms
distinct from those induced by FI-RSV.
Discussion
Five decades of research have documented the mechanisms
behind the detrimental immune responses associated with FI-RSV
vaccines. The current studies indicate that nanoemulsion-inacti-
vated vaccines, such as NE-RSV, may be a safe alternative to FI-
RSV. Given the augmented immune responses observed with
the NE-RSV vaccine, this approach could be important for
Figure 4. NE-RSV vaccination promotes early Th1/Th17-associated cytokines in the lungs. In (A), the levels of Th1/Th17-associated
cytokines were assessed at day 4 post-infection via QPCR of lung RNA. In (B), the levels of CXCL9 and CXCL10 were assessed at day 4 post-infection
via Bioplex multiplex assay of lung homogenates. Each column represents 5 mice per group, and the experiment was repeated with similar results.
*=p,0.05.
doi:10.1371/journal.pone.0021823.g004
Figure 3. Vaccination of mice with NE-RSV attenuates disease following intranasal challenge with live RSV. Immunized mice were
vaccinated intranasally (i.n.) twice at day 0 and day 28 with NE-RSV (10
5 PFU equivalent). Control and vaccinated mice were challenged at day 56
(i.n.) with 10
5 PFU live RSV. In (A), the expression of virus transcripts and were determined at day 4 post-infection via QPCR of lung RNA. (B) depicts
representative histology (Periodic Acid Schiff’s, PAS; Hematoxylin and Eosin, H&E) from control RSV infected and NE-RSV vaccinated mice at day 8
post-infection. In the top two panels, magnification bars are 200 mmi nl e n g t ha n d5 0mm in the bottom two panels. Arrows indicate airway-
associated eosinophils in control RSV infected mice. In (C), the expression of Muc5ac and Gob5 were assessed at day 8 post-infection via QPCR of
lung RNA.
doi:10.1371/journal.pone.0021823.g003
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underdeveloped immune systems. The vaccine is scalable, and
large quantities of virus stocks could be inactivated without the use
of toxic agents, such as formaldehyde or beta-propiolactone. Since
the vaccine is intrinsically microbicidal, vaccine could potentially
be produced and stored without preservatives, such as thimerisol.
The intranasal delivery avoids the use of needles, and, while
potentially mildly unconfortable, is pain-free. Additionally, the
ambient temperature stability of NE-based vaccines makes them
attractive candidates for use in developing countries, where
maintenance of cold storage is problematic. The functional
application of the NE-RSV mucosal vaccine via a non-invasive
intranasal route also allows for easy and safe approaches to
vaccination, especially in children, and focuses the immune
response to the proper location to control viral infections in the
respiratory tract.
Our data indicates that NE-RSV vaccine-induced protection
from RSV infection is associated with enhanced Th1 and Th17
responses. Though the role of Th1/Tc1 responses to RSV is well-
delineated, less is known about the role Th17/Tc17-mediated
responses play in RSV host defense [26]. IL-17A, and other
members of the IL-17 family have well-described roles in host
defense against extracellular bacteria [27,28]. Conversely, inappro-
priate activation of the Th17 axis of inflammation contributes to
autoimmune disease [29,30]. The role of IL-17 in pulmonary host
defense against viral pathogens remains less well explored and may
be dose or pathogen dependent. IL-17 clearly has effects on virus
infected cells, leading to enhanced induction of IL-8 [31]. IL-17
producing CD4+ and CD8+ T cells protect mice against viral
challenge, however cytotoxicity of virally-infected cells by Tc17 cells
may depend on the viral pathogen. Prior work has supported this
concept as Tc17 cells are cytolytic against vaccinia but not influenza
[32,33,34]. Transgenic vaccinia virus expressing IL-23, a Th17
promoting cytokine, is cleared faster than WT virus, in an IL-17-
dependent manner, suggesting that IL-23 promotes clearance of
vaccinia via IL-17 [35]. Thus, IL17 may be important in clearance
Figure 5. NE-RSV vaccination enhances T cell responses upon live viral challenge. Immunized mice were vaccinated intranasally (i.n.) twice
at day 0 and day 28 with NE-RSV (10
5 PFU equivalent). Control and vaccinated mice were challenged at day 56 (i.n.) with 10
5 PFU live RSV. The
frequency and absolute numbers of total CD4+ T cells, total CD8+ T cells, and RSV M82–90 specific CD8+ T cells in the lungs and bronchoalveolar
lavage (BAL) were determined at day 8 post-challenge via flow cytometric analysis of BALs and enzymatically digested lungs. *=p,0.05. Each column
represents 5 mice per group, and the experiment was repeated with similar results.
doi:10.1371/journal.pone.0021823.g005
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experiments will specifically and thoroughly address whether IL-17
has a role in the protective response in this vaccination strategy.
Several mechanisms may play a role in IL-17 mediated responses
to RSV. Evidence suggests that there is cross-regulation of Th2 and
Th17 responses and therefore IL-17 may serve to antagonize the
development of Th2 responses during RSV vaccination [36].
Additionally, IL-17 may play other roles in pulmonary host defense
as well, including augmentation of pulmonary antibody responses
[37]. The chief mechanism ascribed to IL-17 and Th17 cells in the
context of bacterial infection and autoimmune disease is via the
recruitment and activation of neutrophils. Neutrophil recruitment,
in turn, mediates pathogen clearance or host cell damage. The role
of neutrophils in antiviral immunity remains somewhat enigmatic,
but neutrophils produce defensins and can participate in comple-
ment-mediated lysis of RSV infected cells [38,39]. Other studies
from our laboratories suggest that IL-17 may play a multivariate
role in RSV infection. We recently showed that efferent
neutralization of IL-17 in TLR72/2 mice (which produce high
levels of IL-17 in response to RSV) results in attenuated mucus
hypersecretion [40]. Conversely, neutralization of IL-17 in RSV
infected mice post-syngeneic bone marrow transplant impairs viral
clearance (Lindell et al., Manuscript in Preparation). Though we do
not yet know the role of IL-17 in RSV vaccination, IL-17/Th17
differentiation is negatively regulated by IFNa [41], the induction of
which may be lower in the context of an inactivated virus vaccine
and therefore allow the advantageous effects of IL-17 to prevail.
The coexistence of both IgG1 and IgG2a RSV-specific antibodies
observed in the absence of IgE in the NE-RSV vaccinated animals
was unanticipated, but both isotypes were similarly induced in the
serum of non-vaccinated Balb/C mice undergoing secondary RSV
infection (data not shown). These data suggest that the immuno-
globulin isotypes induced by NE-RSV vaccination are similar to
those induced by live viral infection. Immunoglobulin class switch to
IgG2a and IgG2b in mice is promoted by IFNc, whereas IL-4
promotes IgG1 and IgE [42,43]; however IL-4 differentially
Figure 6. NE-RSV immunization promotes clearance of RSV from the lungs. Mice were immunized (i.n.) as previously described, and
challenged oropharyngeally (o.p) with 10
5 PFU live RSV at day 56. In (A), the expression of viral transcripts in the lungs (day 4 post-infection) was
assessed via QPCR. In (B), viral titers were determined at day 4 post-challenge from homogenized lung samples via plaque assay.
doi:10.1371/journal.pone.0021823.g006
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isotype switch, in the absence of the high levels of IL-4 needed to
drive IgE production and suppress IgG1 [44]. Comparatively less is
known about the role of IL-17 in antibody isotype switching,
although one recent study showed that Th17 cells promote Ig class
switching in vitro and in vivo [45]. By using an adoptive transfer
Figure 7. NE-RSV immunization does not promote Th2-mediated immunopotentiation. Mice were vaccinated with NE-RSV as described.
Control and vaccinated mice were challenged at day 56. In (A), airway hyperreactivity was assessed at day 8 post-challenge via invasive
plethysmography. Columns represent the increase in airway resistance following a single, optimized intravenous dose of methacholine. In (B)
cytokine levels in the bronchoalveolar lavage (BAL) and lung homogenate (Lung) were assessed at day 4 and 8 post-challenge. Bars represent the
mean of 6–8 mice per group 6 SEM. *=p,0.05.
doi:10.1371/journal.pone.0021823.g007
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Th17 cells), rather than IL-17, was critical for the induction of IgG1
[45]. Consistent with a role for IL-21 in promoting IgG1, we
observed up-regulation of IL-21 message in NE-RSV vaccinated
mice four days post-RSV challenge (624.66265.4 fold increase,
versus a 5.463.8 fold increase in unvaccinated controls when
comparing both to uninfected mice; p,0.01).
The route of vaccination for NE-RSV (intranasal) may reflect a
predominantly mucosal immune response. The use of this particular
adjuvant allows the generation of a local, effectiveimmune responses
that do not lead to damaging immunopathology after RSV
exposure. Recent studies suggest that the addition of TLR agonists
as adjuvants can enhance the efficacy of vaccines applied to the
mucosal compartment [46,47,48]. While it is yet to be determined
whether the nanoemulsion provided TLR signals during immuni-
zation, further studies with NE-RSV could examine this possibility.
A number of vaccine approaches to RSV have thus far been
tested and/or are currently under consideration, and each of these
has distinct advantages and disadvantages [49,50,51,52]. These
studies indicate that NE-RSV based vaccination promotes both
humoral and cellular immune responses to RSV, and effectively
improves viral clearance, while not promote detrimental, Th2-
mediated immunopathology. This makes a NE-based, inactivated
RSV vaccine an attractive approach to provide safe and effective
protection against RSV-mediated pulmonary disease.
Materials and Methods
Mice
Balb/C mice were purchased from Jackson Laboratories. All
animal work was performed in accordance with the University of
Michigan Committee on Use and Care of Animals policy or the
Institutional Animal Care and Use Committee at Seattle Childrens
Research Institute.
Virus & Vaccine
The nanoemulsion (NE) adjuvant material W805EC used for
these studies was produced by NanoBio. NE is an oil-in-water
emulsion manufactured from ingredients that are Generally
Recognized As Safe (GRAS) with a cationic detergent (cetylpyr-
idinium chloride, CPC) proven safe for human use. The vaccine is
administered nasally and it has shown long-term stability at room
temperature [11]. Mice were vaccinated and challenged with a
subgroup A strain of RSV, referred to as Line 19, originally
isolated from a sick infant at the University of Michigan [53]. Line
19 has been demonstrated in animal models to mimic human
infection by stimulating mucus production using an inoculum of
1610
5 pfu/mouse by intratracheal or oropharyngeal administra-
tion [54]. For cross-reactivity assays, RSV A2 was obtained from
ATCC and Vanderbilt A200 2–20 was provided by Martin Moore
(Emory University). Formalin-inactivated RSV vaccine was
prepared following previously published protocols [55,56]. Briefly,
virus stocks were incubated in the presence of 4% neutral buffered
formalin for 72 hours at 37 degrees. Virus was pelleted from
supernatants via centrifugation for 17 hours at 17,0006 g. The
pellet was resuspended in media and precipitated with 0.05 M
aluminum potassium sulfate, centrifuged at low speed to recover
adsorbed virus (10006g for mins), and resuspended in serum-free
media. Mice were vaccinated intramuscularly (i.m.) with 100 ul
containing 5610
5 PFU equivalent.
Measurement of airway hyperreactivity
AHR was assessed as previously described [57,58,59,60,61,
62,63,64]. AHR was measured using a Buxco mouse plethysmo-
graph which is specifically designed for the low tidal volumes
(Buxco). The mouse to be tested was anesthetized with sodium
pentobarbital and intubated via cannulation of the trachea with an
18-gauge metal tube. The mouse was subsequently ventilated with
a Harvard pump ventilator (tidal volume=0.4 ml, frequen-
cy=120 breaths/min, positive end-expiratory pressure 2.5–
3.0 cm H2O). The plethysmograph was sealed and readings
monitored by computer. As the box is a closed system, a change in
lung volume will be represented by a change in box pressure
(Pbox) that was measured by a differential transducer. Once
baseline levels had stabilized and initial readings were taken, a
methacholine challenge was given via tail vein injection. After
determining a dose–response curve (0.01–0.5 mg), an optimal dose
was chosen, 0.250 mg of methacholine. This dose was used
throughout the rest of the experiments in this study. After the
methacholine challenge, the response was monitored and the
peak airway resistance was recorded as a measure of airway
hyperreactivity.
Quantitative PCR
The smallest lung lobe was removed and homogenized in 1 ml
of Trizol reagent (Invitrogen). RNA was isolated as per
manufacturer’s protocol, and 5 mg was reverse-transcribed to
assess gene expression. Detection of cytokine mRNA in lung
samples was determined using pre-developed primer/probe sets
(Applied Biosystems) and analyzed using an ABI Prism 7500
Sequence Detection System (Applied Biosystems). Transcript
levels of Muc5ac, Gob5 were determined using custom primers, as
previously described [65]. Gapdh was analyzed as an internal
control and gene expression was normalized to Gapdh. Fold
changes in gene expression levels were calculated by comparison
to the gene expression in uninfected mice, which were assigned an
arbitrary value of 1. RSV transcripts were amplified using SYBR
green chemistry, by adapting previously published primer sets to
match the sequence of Line 19 [66,67]:
RSVG sense: 59-CCAAACAAACCCAATAATGATTT-39
RSVG antisense:59-GCCCAGCAGGTTGGATTGT-39
RSVN sense: 59-CATCTAGCAAATACACCATCCA- 39
RSVN antisense: 59-TTCTGCACATCATAATTAGGAGTA-
TCAA – 39
RSVF sense: 59- AATGATATGCCTATAACAAATGATCA-
GAA-39
RSVF antisense: 59- TGGACATGATAGAGTAACTTTGC-
TGTCT-39
The levels of RSV transcripts in the lungs were expressed
relative to the number of copies of GAPDH.
Table 2. Neutrophils and eosinophils in the bronchoalveolar
lavage (BAL) of uninfected, control RSV infected (Ctrl RSV),
and NE-RSV vaccinated (vaccine) mice following
oropharyngeal (OP) RSV challenge.
Neutrophils (%) Eosinophils (%)
Uninfected 1.060.0 0.060.0
Ctrl RSV 5.462.4 0.660.4
Vaccine 15.563.0* 5.463.3
Mice were vaccinated with NE-RSV and challenged with RSV, as described.
Eosinophils and neutrophils were assessed at day 8 post-challenge via
differential counts of cytospins. Each represents the mean of 4–6 mice per
group +/2 SEM.
*=p,0.05 versus control RSV.
doi:10.1371/journal.pone.0021823.t002
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Lungs of mice were excised, weighed, and homogenized in 16
EMEM (Lonza). Homogenates were clarified by centrifugation
(50006g for 10 mins), serial dilutions were made of the supernatant
and added to subconfluent Vero cells. After allowing the virus to
adhere for one hour,the supernatant was removed, and replaced with
0.9% methylcellulose/EMEM. Plaques were visualized on day 5 of
culture by immunohistochemical techniques using goat anti-RSV as
the primary antibody (Millipore), HRP-rabbit anti-goat antibody as
the secondary, and 4-chloronapthol (Pierce) as the substrate.
Serum/BAL ELISA
RSV-specific antibodies were assessed using standard ELISA
techniques. Briefly, high binding 96-well plates were coated with
purified, inactivated RSV (US Biological). After blocking, serial
dilutions of serum or BAL were added to the plates and
incubated overnight at 4 degrees. Bound antibodies were
detected using an HRP-conjugated goat anti-mouse IgG/IgM/
IgA cross-reactive antibody(AbD Serotec), or using isotype
specific detection antibodies (AbD Serotec), and developed with
TMB substrate (KPL). RSV F and G specific ELISAs were
performed similarly, except that plates were coated with purified
recombinant RSV F or RSV G glycoproteins (1.3 ug/ml)
expressed in Baculovirus (Sino Biological). Endpoint titers were
determined via the method of Frey, Di Canzio, and Zurakowski,
in which the OD cutoff is a statistically defined increase over the
OD of samples from naive animals at the same dilution [68].
Cross-reactivity ELISAs were performed by coating plates with
clarified viral supernatant from RSV infected Hep2 cells.
Figure 8. Severe histopathology is associated with formalin-inactivated RSV (FI-RSV) vaccination, but not NE-RSV. Mice were
vaccinated with NE-RSV or FI-RSV, as described, and challenged with live RSV. (A) Representative lung histology (Periodic Acid Schiff’s, PAS) from
unvaccinated control, NE-RSV vaccinated, and FI-RSV vaccinated mice at day 8 post-infection. In (B), the absolute number of eosinophils (Eos),
neutrophils (NEUT), small mononuclear cells (MONO), and macrophages (MAC) in the BALs of unvaccinated, NE-RSV vaccinated, and FI-RSV vaccinated
mice at day 8 post-infection were determined via hemocytometer and differential staining. *=p,0.05, as assessed by ANOVA followed by Tukey’s
multiple comparison test. All other pairwise comparisons were not statistically significant.
doi:10.1371/journal.pone.0021823.g008
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Lung leukocytes were isolated from enzyme dispersed lung
tissue. Right lungs from each mouse were excised, washed in PBS,
minced and digested enzymatically for 45 minutes in 15 ml/lung
of digestion buffer (RPMI, 5% FCS, 1 mg/ml collagenase (Roche
Applied Science), and 30 ug/ml DNase (Sigma-Aldrich). Lung-
Figure 9. NE-RSV vaccination and FI-RSV vaccination promote distinct cytokine and antibody responses. Mice were vaccinated with
NE-RSV or FI-RSV, as described, and challenged with live RSV. In (A), the expression of Th2/Th17 type cytokines was assessed from lung RNA via QPCR.
In (B), the levels of RSV specific serum immunoglobulin and BAL IgA were determined by ELISA. Columns represent the mean of five mice per group
+/2 SEM. *=p,0.05, as assessed by ANOVA followed by Tukey’s multiple comparison test. All other pairwise comparisons were not statistically
significant.
doi:10.1371/journal.pone.0021823.g009
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except that only 5 mls of digestion buffer was used. Following
erythrocyte lysis using ammonium chloride (NH4Cl) buffer, cells
were washed, and resuspended in media (RPMI, 5% FCS). Total
lung leukocyte numbers were assessed in the presence of trypan
blue using a hemocytometer; viability was .85%.
Lymph node restimulation
Lung associated lymph node (LALN) cell suspensions were
plated in duplicate at 1610
6 cells per well followed by
restimulation with either media or RSV (MOI,0.5). Cells were
incubated at 37uC for 24 hours and supernatants collected for
analysis on the BioRad Bioplex 200 system according to the
manufacturer’s protocol. Kits (BioRad) containing antibody beads
to Th cytokines (IL-17, IFNc, IL-4, IL-5, IL-13) were used to assay
for cytokine production in each of the samples.
Lung Protein Analysis
The levels of chemokines and cytokines in lung homogenates
were assessed using multiplex bead-based arrays (Invitrogen), and
analysed on the Bioplex 200 system (BioRad).
Flow cytometric analysis
All antibodies for flow cytometry (BD Pharmingen, Biolegend,
or eBioscience) were used to stain intact cells per manufacturer’s
instructions, and analysed on an LSR II cytometer (BD
Biosciences). RSV M82–90 specific CD8+ T cells were stained
with H-2Kd-restricted SYIGSINNI Pro5H MHC Class I Penta-
mer reagent (Proimmune). Isotype control antibodies were used to
demonstrate specificity of all stains and to establish the criteria for
designated flow cytometry populations.
Histology
Right lobes of the lungs were isolated and immediately fixed in
10% neutral buffered formalin. Lung samples were subsequently
processed, embedded in paraffin, sectioned, and placed on L-
lysine-coated slides, and stained using standard histological
techniques using Hemotoxylin and Eosin (H&E) and Periodic-
acid Schiff (PAS). PAS staining was done to identify mucus and
mucus-producing cells.
Statistics
Data was analyzed using Prism GraphPad software. Unless
otherwise specified, data shown is representative of two or more
experiments. Statistical significance in all experiments was
determined by One-way ANOVA, followed by a Newman-Keuls
post test. Significant differences were regarded as p,0.05.
Statistical comparisions of QPCR data were determined from
normalized Ct values, before conversion to fold-increases.
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